-7/del(7q) occurs in half of myeloid malignancies with adverse-risk cytogenetic features and is associated with poor survival. We identified the spectrum of mutations that co-occur with -7/del(7q) in 40 patients with de novo or therapy-related myeloid neoplasms. -7/del(7q) leukaemias have a distinct mutational profile characterized by low frequencies of alterations in genes encoding transcription factors, cohesin and DNA-methylation-related proteins. In contrast, RAS pathway activating mutations occurred in 50% of cases, a significantly higher frequency than other acute myeloid leukaemias and higher than previously reported. Our data provide guidance for which pathways may be most relevant in the treatment of adverse-risk myeloid leukaemia.
Cytogenetic abnormalities remain the strongest independent predictor for response to therapy and survival in myeloid malignancies. Adverse-risk cytogenetic abnormalities occur in 20-30% of de novo acute myeloid malignancies and 70% of therapy-related myeloid neoplasms (t-MN) (Leith et al, 1997; Smith et al, 2003; Grimwade et al, 2010) . The median overall survival for patients with high-risk abnormalities is <1 year, a rate that has only minimally improved over the last three decades (Smith et al, 2003; Grimwade et al, 2010) . The most common high-risk cytogenetic abnormality is -7/del(7q), identified in half of all t-MN patients and half of adverse-risk de novo acute myeloid leukaemia (AML) (Leith et al, 1997; Smith et al, 2003; Grimwade et al, 2010) . While recent studies have focused on the genomics of low-and intermediaterisk AML, the genetic basis for adverse-risk AML/t-MN remains poorly understood. We previously mapped the commonly deleted segment of chromosome band 7q22 using RNA-sequencing and single nucleotide polymorphism (SNP)-array analysis (McNerney et al, 2013) . We identified the gene encoding the CUX1 transcription-factor (CUX1) to be a highly conserved, haploinsufficient myeloid tumour suppressor located within 7q22 (McNerney et al, 2013) . Herein, we identify the genome-wide spectrum of somatic mutations that co-occur with -7/del(7q) and CUX1 loss. We found that the mutation profile of -7/del(7q) leukaemias is significantly different from other AMLs and reveals therapeutic opportunities for improving the outcome for patients with high-risk disease.
Materials and methods
Methods are provided in Data S1.
Results/Discussion
We identified the somatic mutations in 13 leukaemia samples with -7/del(7q) (University of Chicago, [UC] cohort). Three patients had de novo AML and ten had t-MN (Table S1 ). We included t-MN and de novo AML samples as they are indistinguishable morphologically and clinically (Schoch et al, 2004) , suggesting common biological features. It remains unknown, however, if t-MN and de novo AML with -7/del (7q) also have similar somatic mutations. Four samples had complex karyotypes, and three of these also had del(5q) (Table S1) . Two cases had a recurrent genetic variation as defined by the 2008 World Health Organization category 'AML with recurrent genetic abnormalities' (Swerdlow et al, 2008) , which was inv(3). Complex karyotype, del(5q), and inv (3) frequently co-occur with loss of 7q (Swerdlow et al, 2008) . Paired tumour and normal exome-sequencing was performed on six cases; seven others underwent RNA-sequencing of the leukaemia sample with exome-sequencing of normal tissue. Thus, all samples received paired normal exome sequencing for somatic mutation detection. The median coverage of coding exons for tumour exomes was 1309, 729 for normal exomes, and 309 for RNA-sequenced tumours (Table S1 ). The median percentage of coding bases with sufficient depth for SNP identification (≥89 coverage) was 92Á1% for tumour exomes, 83Á6% for normal exomes, and 37Á6% for RNAsequenced tumours. Copy number analysis was available for eight leukaemia samples (McNerney et al, 2013) .
We identified 40 mutations in the six exome-sequenced cases (Table I) . Twenty-one mutations were Sanger sequenced with a 100% validation rate (Table S2) . Thirtynine mutations were identified in the RNA-sequenced cases of which 30 were verified, with a validation rate of 93Á8% (Table S2) . One RNA-sequenced sample had fusion events identified by RNA-sequencing (McNerney et al, 2013) (Table S1 ). The average number of single nucleotide mutations and indels per sample was six (0Á16 mutations/Mb), which is lower than previous reports (Link et al, 2011; The Cancer Genome Atlas Research Network [TCGA] 2013) . This is possibly due to conservative mutation calling parameters and lower coverage in the current study, particularly for the RNA-sequenced samples. The median number of mutations for the RNA-sequenced samples was 3, compared to 5Á5 in the exomes. There was no difference in the mutation load for t-MN patients as compared to de novo AML; however, there are only three de novo AMLs in this cohort. The fraction of mutations that were transversions was 32Á5% and was similar when restricting the analysis to the t-MN samples (36Á1%), consistent with prior reports (Link et al, 2011; TCGA, 2013) .
Driver mutations in AML genomes predominate in eight functional categories: tumour suppressors, signalling molecules, myeloid transcription factors, DNA-methylation regulators, chromatin modifiers, cohesin, spliceosome components and NPM1 (Table S3) (TCGA, 2013) . Of these, the most frequently altered in the UC cohort was the RAS pathway, with activating mutations in 8/13 (61Á5%) samples ( Fig 1A) . The mutations were comprised of those associated with juvenile myelomonocytic leukaemia (JMML), including activating mutations of NRAS and PTPN11, and inactivating mutations of CBL (Table I ). The next most frequently altered pathway involved chromatin modifiers (4/13 cases, 31%).
There was a paucity of mutations in the other major pathways.
RNA-sequencing to detect somatic mutations is limited to identification of expressed mutations. Mutations in genes that are not expressed, expressed at low levels, or mutations that cause nonsense-mediated decay will be missed. Therefore, to extend our findings to a larger, independent cohort and to exclude the possibility that RNA-sequencing biased the discovery of mutations in specific pathways, mutations in -7/del(7q) AML samples from TCGA were assessed (TCGA, 2013) . Of the 200 TCGA samples with exome or whole genome sequencing, 21 had -7/del(7q) by cytogenetic analysis. Six additional samples with >30 Mb deletions involving 7q identified by SNP array were also included, for a total of 27 cases with -7/del(7q) in the TCGA cohort. -7/del(7q) deletions spanned CUX1 in 22/27 cases, the remaining five cases had deletions that spanned EZH2 on 7q36.
The patterns of mutations seen in the TCGA -7/del(7q) samples reflected the results of the UC cohort ( Fig 1B) . RAS pathway activating mutations were prevalent, occurring in 44% of cases (Table S4 ). These included mutations of NRAS, KRAS, RIT1, and deletions or mutations of NF1. In contrast, RAS pathway mutations occurred in 19% of the other 173 TCGA samples (chi-squared P = 0Á0033). We note that RAS pathway mutations were restricted to those cases with deletions of CUX1, occurring in 12/22 (55%, P = 0Á00014). RAS pathway mutational status did not influence median overall survival within the -7/del(7q) TCGA subset (10Á0 AE 22Á8 months without RAS pathway mutations, n = 15; 9Á4 AE 15Á5 months for patients with RAS pathway mutations, n = 12).
The TCGA cohort replicated the finding that genes encoding chromatin modifiers were mutated at similar rates in -7/ del(7q) cases (41%) as compared to others (30%, P = 0Á24), whereas alterations in other major leukemogenic pathways were underrepresented. There were fewer mutations in the genes encoding the signalling molecules, FLT3 or KIT, (P = 0Á045), the cohesin complex (P = 0Á031), and NPM1 (P = 0Á0034). Thirty percent of -7/del(7q) AML had alterations in the DNA methylation pathway, as compared to 46% of others, but this did not reach statistical significance (P = 0Á12).
Myeloid transcription factor alterations (Table S3) were decreased in -7/del(7q) leukaemias. Whereas 45% of AML samples without -7/del(7q) had disruption of at least one myeloid transcription factor gene, the frequency was 26% (7/ 27) in the TCGA -7/del(7q) cases (P = 0Á061). The frequency of myeloid transcription factor mutations was markedly lower within those TCGA samples with deletions of CUX1, occurring in only 18% (4/22) of cases (P = 0Á014), indicating that CUX1 deletions are mutually exclusive with mutations of other myeloid transcription factor genes.
The high rate of TP53 mutations or deletions (20% UC and 44% TCGA) in -7/del(7q) samples compared to others (5%, P = 0Á0001, TCGA cohort), is driven by the strong association GERP, genomic evolutionary rate profiling score (Cooper et al, 2005) . Cancer Gene Census data was downloaded March 2014 (Futreal et al, 2004) . cBioPortal data (Cerami et al, 2012) (Table S3) . Mutations in genes not in these pathways are not shown. Samples are hierarchically clustered by Pearson correlation coefficients based on the presence or absence of mutations in these pathways using Ward's method. Mutated pathways are shown for the UC cohort (A), the TCGA cohort (B), and the combined UC and TCGA cohorts (C). (D) The frequency of the alteration in the combined UC (n = 13) and TCGA (n = 27) cohorts of -7/del(7q) leukaemias (red bars, n = 40) is shown in comparison to TCGA AML samples without -7/del(7q) (grey bars, n = 173). The number of genes per category is indicated in parentheses. * indicates chi-squared test P < 0Á05 comparing -7/del(7q) TCGA samples versus other TCGA samples. All recurrent genetic abnormalities according to the 2008 World Health Organization classification 'AML with recurrent genetic abnormalities' are indicated (Swerdlow et al, 2008) , with an abbreviation within the relevant pathway. B: BCR-ABL1 fusion; C: CEBPA mutation; i3: inv(3)(q21q26.2) or t(3)(3;3)(q21;q26.2); M: MLLT3-KMT2A fusion; and P: PML-RARA fusion. Abbreviations: TF, transcription factor. Within the UC cohort, t-MN samples are named by TXX and de novo AML samples are named by AXX.
between del(5q) and TP53 mutations (Figs. 1C and 1D ). With one exception, all of the 15 TP53 mutations or deletions in the combined cohorts occurred in samples that also had del(5q) (Cochran-Mantel-Haenszel test P = 3Á5e-07). This is the first description of the genome-wide mutation burden in high-risk myeloid leukaemia with -7/del(7q). The analysis of additional patients in larger studies will be necessary to confirm the current findings. We did not observe differences in the mutational spectrum in t-MN or de novo AML. Across all -7/del(7q) cases, we observed a higher frequency of RAS pathway mutations (50% of UC and TCGA combined) than previously reported (14%) (Side et al, 2004) , suggesting that haploinsufficiency of a gene(s) on chromosome 7 cooperates with RAS in AML pathogenesis. The finding of a low number of transcription factor alterations, particularly in those samples with a deletion of CUX1, is consistent with a transcription factor role for the gene(s) on chromosome 7, such as CUX1 (McNerney et al, 2013) . Of note, CUX1 is mutated in 7-10% of endometrial carcinoma, gastric adenocarcinoma and melanoma (Cerami et al, 2012) . Our analysis of TCGA data revealed that RAS pathway mutations are over twice as frequent in CUX1-mutated solid tumours within these three diseases (P < 0Á01). Indeed, a striking 80% of endometrial and melanoma cancers with mutated CUX1 also have activating RAS pathway mutations, suggesting that cooperation between CUX1 and RAS may be a tumourigenic mechanism that extends beyond haematological malignancies. As drugs targeting the RAS pathway advance, therapeutic inhibition of RAS, in addition to targeting pathways triggered by CUX1 haploinsufficiency, may cooperate to improve the outcome for patients with high-risk myeloid neoplasms.
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